Recent advancements spotlight the efficacy of selpercatinib, a selective RET inhibitor, particularly in non-small cell lung cancer and RET-positive thyroid cancer, even extending to a tissue agnostic approval [5,6]. Here, RET is linked to thyroid cancer.